Targeting the TF-FXa-FIIa-PAR1-axis to reduce thrombo-inflammation might improve AF management strategies by combining proper anticoagulation (“A”); better symptom and rhythm control by reducing adverse remodeling AF progression and HF (“B”); and enabling the treatment of concomitant cardiovascular conditions and risk factors (“C”). This evidence concerns the gene TF and hydrops fetalis.